Cryptic speciation associated with geographic and ecological divergence in two Amazonian Heliconius butterflies

International audienc

Thin Film (High Temperature) Superconducting Radiofrequency Cavities for the Search of Axion Dark Matter

5 pages, 6 figures. v2: minor updates after referee comments, matches published version in IEEEThe axion is a hypothetical particle which is a candidate for cold dark matter. Haloscope experiments directly search for these particles in strong magnetic fields with RF cavities as detectors. The Relic Axion Detector Exploratory Setup (RADES) at CERN in particular is searching for axion dark matter in a mass range above 30 $\mu$eV. The figure of merit of our detector depends linearly on the quality factor of the cavity and therefore we are researching the possibility of coating our cavities with different superconducting materials to increase the quality factor. Since the experiment operates in strong magnetic fields of 11 T and more, superconductors with high critical magnetic fields are necessary. Suitable materials for this application are for example REBa$_2$Cu$_3$O$_{7-x}$, Nb$_3$Sn or NbN. We designed a microwave cavity which resonates at around 9~GHz, with a geometry optimized to facilitate superconducting coating and designed to fit in the bore of available high-field accelerator magnets at CERN. Several prototypes of this cavity were coated with different superconducting materials, employing different coating techniques. These prototypes were characterized in strong magnetic fields at 4.2 K.This project has received funding from the European Union’s Horizon 2020 Research and Innovation programme under Grant Agreement No 730871 (ARIES-TNA). BD and JG acknowledge funding through the European Research Council under grant ERC-2018-StG-802836 (AxScale). We also acknowledge funding via the Spanish Agencia Estatal de Investigacion (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) under project PID2019- 108122GB-C33, and the grant FPI BES-2017-079787 (under project FPA2016-76978-C3-2-P). Furthermore we acknowledge support from SuMaTe RTI2018-095853-B-C21 from MICINN co-financed by the European Regional Development Fund, Center of Excellence award Severo Ochoa CEX2019- 000917-S and CERN under Grant FCCGOV-CC-0208 (KE4947/ATS).With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S).Peer reviewe

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Update in Internal Medicine

More than 500,000 new medical articles are published every year and available time to keep updated is scarcer every day. Nowadays, the task of selecting useful, consistent, and relevant information for clinicians is a priority in many major medical journals. This review has the aim of gathering the results of the most important findings in clinical medicine in the last few years. It is focused on results from randomized clinical trials and well-designed observational research. Findings were included preferentially if they showed solid results, and we avoided as much as possible including only preliminary data, or results that included only non-clinical outcomes. Some of the most relevant findings reported here include the significant benefit of statins in patients with coronary artery disease even with mean cholesterol level. It also provides a substantial review of the most significant trials assessing the effectiveness of IIb/IIIa receptor blockers. In gastroenterology many advances have been made in the H. pylori eradication, and the finding that the cure of H. pylori infection may be followed by gastroesophageal reflux disease. Some new antivirals have shown encouraging results in patients with chronic hepatitis. In the infectious disease arena, the late breaking trials in anti-retroviral disease are discussed, as well as the new trends regarding antibiotic resistance. This review approaches also the role of leukotriene modifiers in the treatment of asthma and discusses the benefit of using methylprednisolone in patients with adult respiratory distress syndrome, among many other advances in internal medicine